# Safety and Efficacy of YB-1113 in Treatment of POI

> **NCT05494723** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Bright Cell, Inc.** · enrollment: 6 (estimated)

## Conditions studied

- POI

## Interventions

- **DRUG:** YB-1113

## Key facts

- **NCT ID:** NCT05494723
- **Lead sponsor:** Bright Cell, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-12-09
- **Primary completion:** 2028-01-09
- **Final completion:** 2028-04-09
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2025-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05494723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05494723, "Safety and Efficacy of YB-1113 in Treatment of POI". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT05494723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*